Silence can speak volumes. That silence is even louder coming from Novo Nordisk, Europe’s most valuable company, which is still reeling from disappointing weight-loss drug results in December on the eve of its latest round of financial results.
The drugmaker behind the medical phenomenon semaglutide, the key ingredient in Wegovy and Ozempic, will go into its full-year results on Wednesday more bruised than it has ever been since its GLP-1 diabetes medications became popularized as weight loss tools for the masses.
